These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 16550384)

  • 1. FDG-PET status following chemoradiotherapy provides high management impact and powerful prognostic stratification in oesophageal cancer.
    Duong CP; Hicks RJ; Weih L; Drummond E; Leong T; Michael M; Thomas RJ
    Eur J Nucl Med Mol Imaging; 2006 Jul; 33(7):770-8. PubMed ID: 16550384
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Significant clinical impact and prognostic stratification provided by FDG-PET in the staging of oesophageal cancer.
    Duong CP; Demitriou H; Weih L; Thompson A; Williams D; Thomas RJ; Hicks RJ
    Eur J Nucl Med Mol Imaging; 2006 Jul; 33(7):759-69. PubMed ID: 16470369
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Value of complete metabolic response by (18)F-fluorodeoxyglucose-positron emission tomography in oesophageal cancer for prediction of pathologic response and survival after preoperative chemoradiotherapy.
    Kim MK; Ryu JS; Kim SB; Ahn JH; Kim SY; Park SI; Kim YH; Song HY; Shin JH; Jung HY; Lee GH; Choi KD; Cho KJ; Kim JH
    Eur J Cancer; 2007 Jun; 43(9):1385-91. PubMed ID: 17512192
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 18F-FDG PET/CT has a high impact on patient management and provides powerful prognostic stratification in the primary staging of esophageal cancer: a prospective study with mature survival data.
    Barber TW; Duong CP; Leong T; Bressel M; Drummond EG; Hicks RJ
    J Nucl Med; 2012 Jun; 53(6):864-71. PubMed ID: 22582047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer.
    Swisher SG; Maish M; Erasmus JJ; Correa AM; Ajani JA; Bresalier R; Komaki R; Macapinlac H; Munden RF; Putnam JB; Rice D; Smythe WR; Vaporciyan AA; Walsh GL; Wu TT; Roth JA
    Ann Thorac Surg; 2004 Oct; 78(4):1152-60; discussion 1152-60. PubMed ID: 15464463
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of metabolic response measured by 18F-FDG-PET in oesophageal cancer patients treated with definitive chemoradiotherapy.
    Onal C; Torun N; Guler OC; Yildirim BA
    Nucl Med Commun; 2016 Dec; 37(12):1282-1289. PubMed ID: 27612030
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The value of ¹⁸F-FDG PET/CT in assessment of metabolic response in esophageal cancer for prediction of histopathological response and survival after preoperative chemoradiotherapy.
    Myslivecek M; Neoral C; Vrba R; Vomackova K; Cincibuch J; Formanek R; Koranda P; Zapletalova J
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2012 Jun; 156(2):171-9. PubMed ID: 22660205
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 2-Fluoro-2-deoxy-D-glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with esophageal carcinoma.
    Swisher SG; Erasmus J; Maish M; Correa AM; Macapinlac H; Ajani JA; Cox JD; Komaki RR; Hong D; Lee HK; Putnam JB; Rice DC; Smythe WR; Thai L; Vaporciyan AA; Walsh GL; Wu TT; Roth JA
    Cancer; 2004 Oct; 101(8):1776-85. PubMed ID: 15386332
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ineffectiveness of ¹⁸F-fluorodeoxyglucose positron emission tomography in the evaluation of tumor response after completion of neoadjuvant chemoradiation in esophageal cancer.
    Piessen G; Petyt G; Duhamel A; Mirabel X; Huglo D; Mariette C
    Ann Surg; 2013 Jul; 258(1):66-76. PubMed ID: 23470576
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The added value of metabolic imaging with FDG-PET in oesophageal cancer: prognostic role and prediction of response to treatment.
    Bombardieri E
    Eur J Nucl Med Mol Imaging; 2006 Jul; 33(7):753-8. PubMed ID: 16733687
    [No Abstract]   [Full Text] [Related]  

  • 11. 15-Year Experience of 18F-FDG PET Imaging in Response Assessment and Restaging After Definitive Treatment of Merkel Cell Carcinoma.
    Byrne K; Siva S; Chait L; Callahan J; Bressel M; Seel M; MacManus MP; Hicks RJ
    J Nucl Med; 2015 Sep; 56(9):1328-33. PubMed ID: 26159592
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The value of
    van Rossum PSN; Fried DV; Zhang L; Hofstetter WL; Ho L; Meijer GJ; Carter BW; Court LE; Lin SH
    Eur J Nucl Med Mol Imaging; 2017 Jan; 44(1):71-80. PubMed ID: 27511188
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Findings on 18F-FDG PET scans after neoadjuvant chemoradiation provides prognostic stratification in patients with locally advanced rectal carcinoma subsequently treated by radical surgery.
    Kalff V; Duong C; Drummond EG; Matthews JP; Hicks RJ
    J Nucl Med; 2006 Jan; 47(1):14-22. PubMed ID: 16391182
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sequential FDG-PET/CT reliably predicts response of locally advanced rectal cancer to neo-adjuvant chemo-radiation therapy.
    Capirci C; Rampin L; Erba PA; Galeotti F; Crepaldi G; Banti E; Gava M; Fanti S; Mariani G; Muzzio PC; Rubello D
    Eur J Nucl Med Mol Imaging; 2007 Oct; 34(10):1583-93. PubMed ID: 17503039
    [TBL] [Abstract][Full Text] [Related]  

  • 15. To evaluate the treatment response of locally advanced esophageal cancer after preoperative chemoradiotherapy by FDG-PET/CT scan.
    Huang JW; Yeh HL; Hsu CP; Lu YY; Chuang CY; Lin JC; Lin JF; Chang CF
    J Chin Med Assoc; 2015 Apr; 78(4):229-34. PubMed ID: 25557468
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of initial fluorodeoxyglucose-PET in esophageal cancer: a prospective study.
    Cheze-Le Rest C; Metges JP; Teyton P; Jestin-Le Tallec V; Lozac'h P; Volant A; Visvikis D
    Nucl Med Commun; 2008 Jul; 29(7):628-35. PubMed ID: 18528185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Postchemoradiotherapy positron emission tomography predicts pathologic response and survival in patients with esophageal cancer.
    Jayachandran P; Pai RK; Quon A; Graves E; Krakow TE; La T; Loo BW; Koong AC; Chang DT
    Int J Radiat Oncol Biol Phys; 2012 Oct; 84(2):471-7. PubMed ID: 22381904
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic significance of novel ¹⁸F-FDG PET/CT defined tumour variables in patients with oesophageal cancer.
    Foley KG; Fielding P; Lewis WG; Karran A; Chan D; Blake P; Roberts SA
    Eur J Radiol; 2014 Jul; 83(7):1069-1073. PubMed ID: 24794862
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prediction of outcome with FDG-PET in definitive chemoradiotherapy for esophageal cancer.
    Atsumi K; Nakamura K; Abe K; Hirakawa M; Shioyama Y; Sasaki T; Baba S; Isoda T; Ohga S; Yoshitake T; Shinoto M; Asai K; Honda H
    J Radiat Res; 2013 Sep; 54(5):890-8. PubMed ID: 23520267
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Limited predictive value of FDG-PET for response assessment in the preoperative treatment of esophageal cancer: results of a prospective multi-center trial (SAKK 75/02).
    Klaeser B; Nitzsche E; Schuller JC; Köberle D; Widmer L; Balmer-Majno S; Hany T; Cescato-Wenger C; Brauchli P; Zünd M; Pestalozzi BC; Caspar C; Albrecht S; von Moos R; Ruhstaller T
    Onkologie; 2009 Dec; 32(12):724-30. PubMed ID: 20016233
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.